StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.36−0.02 (-6.17%)

Close on Nov 17, 2026Market cap $4.67MP/E –Yield –

Lantern Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Lantern Pharma's ebitda for the twelve months ending Sep 30, 2026 was -$16.48M. For fiscal 2025 it was -$17.96M. The highest annual figure on record is -$12.58M in fiscal 2021.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.96M–
FY2024Dec 31, 2024-$22.20M–
FY2023Dec 31, 2023-$17.86M–
FY2022Dec 31, 2022-$14.42M–
FY2021Dec 31, 2021-$12.58M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$5.37M–
Q2 FY2026Jun 30, 2026-$3.50M–
Q1 FY2026Mar 31, 2026-$3.40M–
Q4 FY2025Dec 31, 2025-$4.20M–
Q3 FY2025Sep 30, 2025-$4.35M–
Q2 FY2025Jun 30, 2025-$4.65M–
Q1 FY2025Mar 31, 2025-$4.77M–
Q4 FY2024Dec 31, 2024-$5.89M–
Q3 FY2024Sep 30, 2024-$5.18M–
Q2 FY2024Jun 30, 2024-$5.40M–
Q1 FY2024Mar 31, 2024-$5.73M–
Q4 FY2023Dec 31, 2023-$4.87M–
Q3 FY2023Sep 30, 2023-$3.52M–
Q2 FY2023Jun 30, 2023-$5.19M–
Q1 FY2023Mar 31, 2023-$4.28M–
Q4 FY2022Dec 31, 2022-$3.82M–
Q3 FY2022Sep 30, 2022-$2.14M–
Q2 FY2022Jun 30, 2022-$4.39M–
Q1 FY2022Mar 31, 2022-$4.06M–
Q4 FY2021Dec 31, 2021-$3.51M–
Q3 FY2021Sep 30, 2021-$4.15M–
Q2 FY2021Jun 30, 2021-$2.48M–
Q3 FY2020Sep 30, 2020-$1.70M–
Q2 FY2020Jun 30, 2020-$832.76K–

More Lantern Pharma figures

See a number that looks wrong?